Evidence map›Paper›PMID 33603337›Full record

ReviewDrug design, development and therapy2021

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date.

Mohamad Moussa, Athanasios Papatsoris, Mohamed Abou Chakra, Athanasios Dellis

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug design, development and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  2. Nectin-4: a Novel Therapeutic Target for Skin Cancers.Current treatment options in oncology · 2022
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohamad MoussaDepartment of Urology, Al Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon.
Athanasios Papatsoris2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Mohamed Abou ChakraDepartment of Urology, Al Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon.
Athanasios Dellis2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nowadays the therapeutic landscape for advanced and metastatic urothelial carcinoma continues to evolve. The recent regulatory approval of enfortumab vedotin (EV) for the treatment of advanced urothelial cancer confirms the evolving role of antibody-drug conjugates. EV demonstrates a favorable profile in heavily pretreated patients with locally advanced or metastatic urothelial carcinoma. Early survival reports demonstrate a significant antitumor effectiveness along with a rather acceptable safety profile in a difficult-to-treat population.

Indexed as

Antibodies, MonoclonalAntineoplastic AgentsCarcinoma, Transitional CellHumansAntibodies, MonoclonalAntineoplastic Agentsenfortumab vedotinbladder cancerenfortumab vedotinmetastasisurothelial cancer

Identifiers

PMID33603337
PMCPMC7886109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.